A Phase 1/2 interventional study of LQT-1213 and Placebo in Long QT Syndrome, sponsored by Thryv Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by Thryv Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.
Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 41st registered.
101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.
Browse Long QT Syndrome studies →7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thryv Therapeutics, Inc. · Sites in United States
Ages 15+
Washington University School of Medicine · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 4 · Phase 3 2 · Phase 4 5
First in 1985; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 45 across 46 interventional studies indexed under Long QT Syndrome.
Median enrollment 44 across the 28 interventional studies, 96 across the 16 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 44 have an industry lead sponsor. The 10 most frequent:
Thryv Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Thryv Therapeutics, Inc. has 3 studies filed under Long QT Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Long QT Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277582Phase 3Thryv Therapeutics, Inc.Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | 2027-06-30 |
| NCT04336644Washington University School of MedicineContinuous Versus Intermittent cARdiac Electrical moNitorinG | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Long QT Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects. This is a 2-treatment, 2-period crossover study with approximately up to 28 healthy subjects, with screening procedures within 28 days of enrolment.
Part 2: This is a Phase 2a, single-blind, placebo run-in, multiple-dose safety study to evaluate the safety, tolerability, and PK of LQT-1213 in patients diagnosed with LQT2 or LQT3. Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be recruited.
Part 1: This is a 2-treatment, 2-period crossover study. Approximately 28 healthy subjects, with the attempt to balance for sexes, will be enrolled to complete approximately up to 20 subjects in the study. In both treatment periods, all subjects will receive dofetilide on Days 1 and 2 of each period. Randomization will take place before Day 3 of Period 1. Subjects will be randomly assigned to 1 of 2 treatment sequences (AB or BA).
Part 2: Up to 12 participants with LQT2 and up to 12 participants with LQT3 will be enrolled. After initial screening, which may be conducted remotely by the CRU, individual participants with LQT2 or LQT3 will undergo a 1-day, single-blind placebo run-in period followed by 3 dosing days of LQT-1213 administered TID (the last dosing day will have a single dose). Participants will be discharged from the CRU on Day 5. Approximately 7 days after discharge from the CRU, the Follow-up Visit will be conducted remotely via telephone call.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part1:
Female subjects of (ie, ovulating, premenopausal, and not surgically sterile) must use a highly effective regimen during their participation in the study and for 30 days after the last administration of study drug. Highly effective contraceptive methods are defined as those with \<1% failure rate per year. Acceptable methods of contraception for female subjects enrolled in the study include the following:
Male subjects and their partners must use highly effective methods of contraception (ie, condom and spermicide) for the entire duration of the study. Male subjects must continue to use contraception and refrain from fathering a child and sperm donation for 90 days after the last administration of study drug. Acceptable methods of contraception for male subjects enrolled in the study include the following:
Part 2:
Female participants of childbearing potential (ie, ovulating, premenopausal, and not surgically sterile) must use a highly effective contraceptive regimen during their participation in the study and for 30 days after the last administration of study drug. Highly effective contraceptive methods are defined as those with \<1% failure rate per year. Acceptable methods of contraception for female participants enrolled in the study include the following:
Male participants and their partners must use highly effective methods of contraception (ie, condom and spermicide) for the entire duration of the study. Male participants must continue to use contraception and refrain from fathering a child and sperm donation for 90 days after the last administration of study drug. Acceptable methods of contraception for male participants enrolled in the study include the following:
LQT2 or LQT3 mutation:
The first 2 participants with LQT2 require having an ICD before further participants with LQT2 are enrolled and the first 2 participants with LQT3 require having an ICD before further participants with LQT3 are enrolled. This stipulation may be altered based on agreement between the principal investigator and Sponsor based on emerging data. The ICD implantation must have been at least 2 months before Screening.
Note: Subsequent participants may or may not have had an ICD. The results of the ICD interrogation within the last 6 months should be available for review unless waived by the investigator and sponsor.
Exclusion Criteria:
Part 1:
Subject is unable to refrain from or anticipates the use of any drug, including prescription and nonprescription medications (with the exception of hormonal ), herbal preparations, or vitamin supplements beginning 14 days before the first dose and until the end of the study. After dosing, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the investigator or designee.
Subject has a history of high alcohol consumption within 9 months before Screening, defined as an average weekly intake of >14 units for males or >10 units for females.
One unit is equivalent to 8 g of alcohol: a half-pint (\~240 mL) of beer, 1 glass (125 mL) of wine, or 1 measure (25 mL) of spirits.
Part 2:
Participant is not permitted to use/consume the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequence A :Dofetilide 500 μg BID (Days 1-8) and LQT-1213 TID 0.25 mg/kg (Days 3 and 4), 0.50 mg/kg (Days 5 and 6), and 0.70 mg/kg on Days 7 and 8. After adequate washout, Dofetilide 500 μg BID (Days 1-8) and placebo (Days 3-8).
Drug: LQT-1213 · Drug: Placebo · Drug: Dofetilide 250 μg Cap
Sequence B : Dofetilide 500 μg BID, orally (Days 1-8) and placebo TID (Days 3-8). After adequate washout, Dofetilide 500 μg BID, orally (Days 1-8) and LQT-1213 3 times a day (TID) 0.25 mg/kg (Days 3 and 4), 0.50 mg/kg (Days 5 and 6), and 0.70 mg/kg on Days 7 and 8.
Drug: LQT-1213 · Drug: Placebo · Drug: Dofetilide 250 μg Cap
LQT-1213 16 mg TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4. Day 1 was placebo.
Drug: LQT-1213 · Drug: Placebo
LQT-1213 7 mg TID (at time 0, 8 and 16 hours) on Days 2-4, with a final single morning dose on Day 4. Day 1 was placebo.
Drug: LQT-1213 · Drug: Placebo
LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Matching Placebo
Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.0 hours after administration of study treatment on Day 4.
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.5 hours after administration of study treatment on Day 4
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.0 hours after administration of study treatment on Day 4
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.5 hours after administration of study treatment on Day 4
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 4.0 hours after administration of study treatment on Day 4
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.0 hours after administration of study treatment on Day 6
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.5 hours after administration of study treatment on Day 6
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.0 hours after administration of study treatment on Day 6
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.5 hours after administration of study treatment on Day 6
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 4.0 hours after administration of study treatment on Day 6
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.0 hours after administration of study treatment on Day 8
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 2.5 hours after administration of study treatment on Day 8
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.0 hours after administration of study treatment on Day 8
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 3.5 hours after administration of study treatment on Day 8
Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
Time frame: 4.0 hours after administration of study treatment on Day 8
Part 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-3
The primary outcome is to measure the incidence of treatment emergent adverse events (TEAEs).
Time frame: up to day 12
Part 1: Pharmacokinetic LQT-1213 AUC0-t
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
Time frame: 0 to 24 hours post-dose on Day 8
Part 1: Pharmacokinetic Dofetilide AUC0-t
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
Time frame: 0 to 24 hours post-dose on Day 8
Part 1: Pharmacokinetic LQT-1213 AUCtau
AUCtau = Area under the curve from time 0 to 8.0 hours
Time frame: Day 4,6, 8
Part 1: Pharmacokinetic Dofetilide AUCtau
AUCtau = Area under the curve from time 0 to 12 hours
Time frame: Day 4,6,8
Part 1: Pharmacokinetic LQT-1213 Cmax
Maximum observed plasma drug concentration
Time frame: Day 4,6,8
Part 1: Pharmacokinetic Dofetilide Cmax
Maximum observed plasma drug concentration
Time frame: Day 4,6, 8
Part 1: Pharmacokinetic LQT-1213 Tmax
Time to the maximum observed plasma concentration
Time frame: Day 4,6,8
Part 1: Pharmacokinetic Dofetilide Tmax
Time to the maximum observed plasma concentration
Time frame: Day 4,6,8
Part 1: Pharmacokinetic LQT-1213 t1/2
Terminal half-life
Time frame: Day 8
Part 1: Pharmacokinetic Dofetilide t1/2
Terminal half-life
Time frame: Day 8
Part 1: Number of Treatment Emerging Adverse Events (TEAEs)
Part 1: Number of Treatment Emerging Adverse Events (TEAEs) that occurred following administration of dofetilide Day1 up to Day 10 period 1 and in period 2 from Day 1 to up to the follow-up visit at Day 17.
Time frame: Period 1 from Day 1 to Day 10 and Period 2 from Day 1 up to Day 17.
Part 2: Pharmacokinetic LQT-1213 AUC0-t
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
Time frame: Day 4 Pre-dose up to 29 hours post-dose administration
Part 2: Pharmacokinetic LQT-1213 AUCtau
Pharmacokinetic LQT-1213 AUCtau (time 0 to 8 hours)
Time frame: day 2 and day 4
Part 2: Pharmacokinetic LQT-1213 Cmax
Maximum observed plasma drug concentration
Time frame: day 2 and day 4
Part 2: Pharmacokinetic LQT-1213 Tmax
Time to the maximum observed plasma concentration
Time frame: Day 2 and Day 4
Part 2: Pharmacokinetic LQT-1213 t1/2
Part 2: Pharmacokinetic LQT-1213 terminal half-life t1/2
Time frame: Day 4
Part 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 1 hour after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose
QTcF values at each timepoint on Day 4 were compared to the time-matched QTcF value on Day 1 (placebo) using the paired t-test.
Time frame: 2 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 3 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 4 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 6 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 8 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 10 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 12 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 1 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 2 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test, which was the same as analyzing the difference of the time-matched QTcF values using one-sample t test.
Time frame: 3 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 4 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 6 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 8 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 10 hours after administration of study treatment on Day 4.
Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose)
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
Time frame: 12 hours after administration of study treatment on Day 4.
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo)
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).
Time frame: Day 4
Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
Time frame: Day 4
Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
Time frame: Day 4
Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
Time frame: Day 4
Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms)
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
Time frame: Day 4
| Milestone | Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With Placebo | Part 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TID | Part 2: TID Dosing of LQT-1213 16 mg (48 mg Daily) | Part 2: TID Dosing of LQT-1213 7 mg (21 mg Daily) |
|---|---|---|---|---|
| Started | 15 | 15 | 6 | 6 |
| Completed | 12 | 11 | 6 | 6 |
| Not completed | 3 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 4 | 0 | 0 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.25 mg/kg (Day 4) | Dofetilide + Placebo (Day 4) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 40.8 ± 11.08 | 50.3 ± 14.77 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.25 mg/kg (Day 4) | Dofetilide + Placebo (Day 4) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 43.3 ± 11.76 | 48.0 ± 11.42 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.25 mg/kg (Day 4) | Dofetilide + Placebo (Day 4) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 40.9 ± 11.05 | 48.6 ± 12.93 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.25 mg/kg (Day 4) | Dofetilide + Placebo (Day 4) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 43.4 ± 13.01 | 46.4 ± 11.33 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.25 mg/kg (Day 4) | Dofetilide + Placebo (Day 4) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 39.2 ± 10.85 | 43.3 ± 13.83 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.50 mg/kg (Day 6) | Dofetilide + Placebo (Day 6) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 42.4 ± 15.89 | 43.9 ± 16.41 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.50 mg/kg (Day 6) | Dofetilide + Placebo (Day 6) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 43.7 ± 14.74 | 42.5 ± 16.93 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.50 mg/kg (Day 6) | Dofetilide + Placebo (Day6) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 42.3 ± 12.57 | 40.4 ± 16.70 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | LQT-1213 0.50 mg/kg (Day 6) | Dofetilide + Placebo (Day 6) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 42.0 ± 13.40 | 40.7 ± 15.45 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.50 mg/kg (Day 6) | Dofetilide + Placebo (Day 6) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 38.5 ± 14.64 | 35.3 ± 17.14 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.70 mg/kg (Day 8) | Dofetilide + Placebo (Day 8) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 45.0 ± 14.31 | 48.9 ± 13.94 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | LQT-1213 0.70 mg/kg (Day 8) | Dofetilide + Placebo (Day 8) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 46.6 ± 14.23 | 46.8 ± 11.45 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.70 mg/kg (Day 8) | Dofetilide + Placebo (Day 8) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 46.4 ± 15.18 | 48.0 ± 13.24 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.70 mg/kg (Day 8) | Dofetilide + Placebo (Day 8) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 44.4 ± 13.84 | 48.3 ± 12.34 |
The primary outcome is time-based comparison in the change from baseline (baseline defined as Day 1 of Period 1 and Day 1 of Period 2 mean predose QTc) ΔΔQTc by Fridericia's formula (QTcF) during peak dofetilide exposure between dofetilide and placebo treatment, and the dofetilide and LQT-1213 treatment.
| msec | Dofetilide + LQT-1213 0.70 mg/kg (Day 8) | Dofetilide + Placebo (Day 8) |
|---|---|---|
| Part 1: Pharmacodynamics: By-time Point Analysis for QTc on LQT-1213 Versus Placebo | 41.4 ± 12.25 | 45.7 ± 11.75 |
The primary outcome is to measure the incidence of treatment emergent adverse events (TEAEs).
| TEAE | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) | Placebo in LQT-1213 16 mg TID (48 mg) | Placebo in LQT-1213 7 mg TID (21 mg) |
|---|---|---|---|---|
| Part 2: Safety and Tolerability of Oral LQT-1213 in Participants With LQT-2 or LQT-3 | 4 | 3 | 1 | 2 |
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
| h*ng/ml | LQT-1213 TID 0.70 mg/kg |
|---|---|
| Part 1: Pharmacokinetic LQT-1213 AUC0-t | 13221.182 ± 47.6 |
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
| h*ng/ml | Dofetilide 500 μg + Placebo Day 8 | Dofetilide 500 μg + LQT-1213 |
|---|---|---|
| Part 1: Pharmacokinetic Dofetilide AUC0-t | 50.160 ± 18.6 | 51.863 ± 17.1 |
AUCtau = Area under the curve from time 0 to 8.0 hours
| h*ng/ml | LQT-1213 0.25 mg/kg (Day 4) TID | LQT-1213 0.50 mg/kg (Day 6) TID | LQT-1213 0.70 mg/kg (Day 8) TID |
|---|---|---|---|
| Part 1: Pharmacokinetic LQT-1213 AUCtau | 2735.793 ± 47.9 | 5433.729 ± 49.6 | 8763.318 ± 48.0 |
AUCtau = Area under the curve from time 0 to 12 hours
| h*ng/ml | Dofetilide 500 μg + Placebo (Day 4) | Dofetilide 500 μg + Placebo (Day 6) | Dofetilide 500 μg +Placebo (Day 8) | Dofetilide + LQT-1213 (Day 4) | Dofetilide + LQT-1213 (Day 6) | Dofetilide + LQT-1213 (Day 8) |
|---|---|---|---|---|---|---|
| Part 1: Pharmacokinetic Dofetilide AUCtau | 36.350 ± 17.3 | 35.916 ± 15.3 | 37.075 ± 16.0 | 35.142 ± 18.4 | 36.390 ± 16.6 | 38.227 ± 15.3 |
Maximum observed plasma drug concentration
| ng/ml | LQT-1213 0.25 mg/kg (Day 4) TID | LQT-1213 0.50 mg/kg (Day 6) TID | LQT-1213 0.70 mg/kg (Day 8) TID |
|---|---|---|---|
| Part 1: Pharmacokinetic LQT-1213 Cmax | 501.739 ± 48.0 | 1013.942 ± 52.1 | 1612.274 ± 48.5 |
Maximum observed plasma drug concentration
| ng/ml | Dofetilide 500 μg (Day 4) | Dofetilide 500 μg (Day 6) | Dofetilide 500 μg (Day 8) | Dofetilide + LQT-1213 (Day 4) | Dofetilide + LQT-1213 (Day 6) | Dofetilide + LQT-1213 (Day 8) |
|---|---|---|---|---|---|---|
| Part 1: Pharmacokinetic Dofetilide Cmax | 4.367 ± 18.7 | 4.394 ± 16.9 | 4.580 ± 16.8 | 4.184 ± 19.0 | 4.438 ± 19.6 | 4.727 ± 20.6 |
Time to the maximum observed plasma concentration
| hours | LQT-1213 0.25 mg/kg (Day 4) TID | LQT-1213 0.50 mg/kg (Day 6) TID | LQT-1213 0.70 mg/kg (Day 8) TID |
|---|---|---|---|
| Part 1: Pharmacokinetic LQT-1213 Tmax | 1.012 (0.98 to 6.00) | 1.114 (0.98 to 5.06) | 1.999 (0.99 to 5.05) |
Time to the maximum observed plasma concentration
| hours | Dofetilide 500 μg (Day 4) | Dofetilide 500 μg (Day 6) | Dofetilide 500 μg (Day 8) | Dofetilide + LQT-1213 (Day 4) | Dofetilide + LQT-1213 (Day 6) | Dofetilide + LQT-1213 (Day 8) |
|---|---|---|---|---|---|---|
| Part 1: Pharmacokinetic Dofetilide Tmax | 2.012 (1.00 to 6.00) | 2.003 (1.00 to 3.52) | 2.017 (1.00 to 4.01) | 2.015 (1.00 to 451) | 2.008 (1.00 to 5.51) | 2.504 (1.01 to 4.02) |
Terminal half-life
| hours | LQT-1213 TID 0.70 mg/kg |
|---|---|
| Part 1: Pharmacokinetic LQT-1213 t1/2 | 8.374 ± 22.0 |
Terminal half-life
| hours | Dofetilide 500 μg + Placebo Day 8 | Dofetilide + LQT-1213 (Day 8) |
|---|---|---|
| Part 1: Pharmacokinetic Dofetilide t1/2 | 7.139 ± 16.2 | 7.341 ± 14.6 |
Part 1: Number of Treatment Emerging Adverse Events (TEAEs) that occurred following administration of dofetilide Day1 up to Day 10 period 1 and in period 2 from Day 1 to up to the follow-up visit at Day 17.
| TEAE | Dofetilide | Dofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4) | Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6) | Dofetilide + High Dose LQT-1213 TID 0.70 mg/kg (Days 7 and 8) | Dofetilide + Placebo |
|---|---|---|---|---|---|
| Part 1: Number of Treatment Emerging Adverse Events (TEAEs) | 12 | 6 | 12 | 1 | 25 |
Area under the concentration-time curve (AUC) from time 0 to the time of the last measurable concentration
| h*ng/ml | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) |
|---|---|---|
| Part 2: Pharmacokinetic LQT-1213 AUC0-t | 5968 ± 30.9 | 2109 ± 19.5 |
Pharmacokinetic LQT-1213 AUCtau (time 0 to 8 hours)
| h*ng/ml | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) |
|---|---|---|
| Day 2 | 2214 ± 41.7 | 635.3 ± 22.8 |
| Day 4 | 3314 ± 32.3 | 1153 ± 28.0 |
Maximum observed plasma drug concentration
| ng/ml | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) |
|---|---|---|
| Day 2 | 470.9 ± 46.5 | 116.4 ± 23.8 |
| Day 4 | 562.9 ± 44.4 | 195.1 ± 33.9 |
Time to the maximum observed plasma concentration
| ng/ml | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) |
|---|---|---|
| Day 2 | 1.523 (1.01 to 4.01) | 1.268 (1.00 to 2.01) |
| Day 4 | 1.534 (0.98 to 4.01) | 1.781 (1.02 to 5.00) |
Part 2: Pharmacokinetic LQT-1213 terminal half-life t1/2
| hours | LQT-1213 16 mg TID (48 mg Daily) | LQT-1213 7mg Tid (21 mg Daily) |
|---|---|---|
| Part 2: Pharmacokinetic LQT-1213 t1/2 | 11.97 ± 11.8 | 9.982 ± 9.8 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | LQT-1213 16 mg TID (48 mg Daily) Day 4 | Placebo TID (Day1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF - 1 Hour Post Dose | 519.17 ± 32.344 | 514.89 ± 29.569 |
QTcF values at each timepoint on Day 4 were compared to the time-matched QTcF value on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing of Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose | 520.06 ± 31.231 | 513.28 ± 23.733 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | Placebo TID Dosing Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose | 513.94 ± 26.410 | 530.00 ± 39.838 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing of Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose | 514.61 ± 28.450 | 523.67 ± 32.158 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing of Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose | 520.89 ± 26.741 | 531.56 ± 32.897 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose | 503.61 ± 22.106 | 507.61 ± 23.640 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose | 521.00 ± 9.78 | 511.22 ± 22.872 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) | TID Dosing Placebo (Day 1) |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose | 519.42 ± 26.753 | 522.11 ± 23.167 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 1 Hour Post-dose (Low Dose) | 524.39 ± 29.611 | 521.22 ± 33.791 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 2 Hours Post-dose (Low Dose) | 531.72 ± 38.880 | 525.94 ± 29.837 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test, which was the same as analyzing the difference of the time-matched QTcF values using one-sample t test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 3 Hours Post-dose (Low Dose) | 538.22 ± 38.584 | 523.06 ± 33.857 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 4 Hours Post-dose (Low Dose) | 535.72 ± 34.812 | 522.17 ± 35.036 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 6 Hours Post-dose (Low Dose) | 530.67 ± 43.213 | 530.17 ± 32.590 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 8 Hours Post-dose (Low Dose) | 522.67 ± 33.363 | 516.94 ± 51.848 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 10 Hours Post-dose (Low Dose) | 530.39 ± 40.667 | 514.78 ± 38.749 |
QTcF values at each timepoint on Days 4 were compared to the time-matched QTcF values on Day 1 (placebo) using the paired t-test.
| msec | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) | TID Dosing Placebo Day 1 |
|---|---|---|
| Part 2: Time-matched Placebo-corrected QTcF at 12 Hours Post-dose (Low Dose) | 536.11 ± 44.465 | 518.89 ± 39.724 |
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 2103.69 ± 130.872 | 2066.69 ± 113.850 |
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 1582.06 ± 100.213 | 1549.69 ± 85.553 |
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 4173.19 ± 236.787 | 4128.64 ± 224.746 |
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 6225.35 ± 323.651 | 6193.67 ± 314.325 |
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) |
|---|---|---|
| Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 2099.44 ± 132.566 | 2137.25 ± 150.766 |
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 7 mg (21 mg Daily) |
|---|---|---|
| Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 1574.94 ± 101.583 | 1602.28 ± 112.284 |
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 7 mg Day 4 (21 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 4192.47 ± 279.304 | 4248.69 ± 290.144 |
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo).
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 7 mg (21 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 7 mg TID) Compared to the Time-matched on Day 1 (Placebo) | 6257.86 ± 445.699 | 6368.25 ± 444.031 |
QTcF area under the curve on Day 4 (2 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (2 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC2-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms) | 2175.83 ± 85.532 | 2131.54 ± 69.025 |
QTcF area under the curve on Day 4 (3 to 6 hours; LQT-1213) was compared to QTcF AUC on Day 1 (3 to 6 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC3-6 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms) | 1636.33 ± 68.013 | 1598.46 ± 51.804 |
QTcF area under the curve on Day 4 (0 to 8 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 8 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-8 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms) | 4308.79 ± 135.627 | 4255.38 ± 138.707 |
QTcF area under the curve on Day 4 (0 to 12 hours; LQT-1213) was compared to QTcF AUC on Day 1 (0 to 12 hours; placebo) for subjects with a Day 1 Pre-Dose (Baseline 1) QTcF \>= 500 ms
| msec*hour | TID Dosing of Placebo Day1 | TID Dosing of LQT-1213 16 mg Day 4 (48 mg Daily) |
|---|---|---|
| Part 2: ΔAUC0-12 Hours QTcF Values on Day 4 (LQT-1213 16 mg TID) Compared to the Time-matched on Day 1 (Placebo) Subgroup Analysis (≥ 500ms) | 6413.29 ± 175.189 | 6369.04 ± 200.818 |
Collected over Part 1 : Period 1 (Day 1 to Day 10) and Period 2 (Day 1 to Day 17). Part 2: 12 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dofetilide | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Dofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4) | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6) | 0/29 (0%) | 0/29 (0%) | 2/29 (6.9%) |
| Dofetilide + High Dose LQT-1213 0.70 mg/kg on (Days 7 and 8) | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Dofetilide + Placebo | 0/25 (0%) | 0/29 (0%) | 4/29 (13.8%) |
| LQT-1213 16 mg TID | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| LQT-1213 7 mg TID | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo Matching LQT-1213 16 mg TID | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo Matching LQT-1213 7 mg TID | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Dofetilide | Dofetilide + Low Dose LQT-1213 TID 0.25 mg/kg (Days 3 and 4) | Dofetilide + Mid Dose LQT-1213 TID 0.50 mg/kg (Days 5 and 6) | Dofetilide + High Dose LQT-1213 0.70 mg/kg on (Days 7 and 8) | Dofetilide + Placebo | LQT-1213 16 mg TID | LQT-1213 7 mg TID | Placebo Matching LQT-1213 16 mg TID | Placebo Matching LQT-1213 7 mg TID |
|---|---|---|---|---|---|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 2/6 | 1/6 | 0/6 | 0/6 |
| PollakiuriaRenal and urinary disorders | 0/30 | 0/29 | 0/29 | 0/25 | 2/29 | 0/6 | 0/6 | 0/6 | 1/6 |
| Skin tightnessSkin and subcutaneous tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 0/6 | 1/6 | 0/6 | 1/6 |
| Skin warmSkin and subcutaneous tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 0/6 | 1/6 | 0/6 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 1/6 | 0/6 | 0/6 | 0/6 |
| Rhinitis atrophicRespiratory, thoracic and mediastinal disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 1/6 | 0/6 | 0/6 | 0/6 |
| Electrode site irritationSkin and subcutaneous tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 0/29 | 0/6 | 0/6 | 1/6 | 0/6 |
| Vessel puncture site painGeneral disorders | 0/30 | 0/29 | 2/29 | 0/25 | 4/29 | 0/6 | 0/6 | 0/6 | 0/6 |
| Dry skinSkin and subcutaneous tissue disorders | 0/30 | 0/29 | 0/29 | 0/25 | 2/29 | 0/6 | 0/6 | 0/6 | 0/6 |
| PalpitationsCardiac disorders | 0/30 | 0/29 | 0/29 | 0/25 | 2/29 | 0/6 | 0/6 | 0/6 | 0/6 |
| Age, Continuous(years) | Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With Placebo | Part 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TID | Part 2: TID Dosing of LQT-1213 16 mg | Part 2: TID Dosing of LQT-1213 7mg | Total |
|---|---|---|---|---|---|
| Mean | 43.3 ± 12.4 | 42.2 ± 9.13 | 42.0 ± 13.71 | 40.3 ± 8.33 | 42 ± 10.84 |
| Sex: Female, Male(Participants) | Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With Placebo | Part 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TID | Part 2: TID Dosing of LQT-1213 16 mg | Part 2: TID Dosing of LQT-1213 7mg | Total |
|---|---|---|---|---|---|
| Female | 5 | 4 | 4 | 5 | 18 |
| Male | 10 | 11 | 2 | 1 | 24 |
| Race (NIH/OMB)(Participants) | Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With Placebo | Part 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TID | Part 2: TID Dosing of LQT-1213 16 mg | Part 2: TID Dosing of LQT-1213 7mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 6 | 0 | 0 | 14 |
| White | 6 | 7 | 6 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| body mass index(kg/m2) | Part 1: Arm A: Dofetilide With Dose-escalating LQT-1213 TID Followed by Dofetilide With Placebo | Part 1: Arm B: Dofetilide With Placebo Followed by Dofetilide With LQT-1213 TID | Part 2: TID Dosing of LQT-1213 16 mg | Part 2: TID Dosing of LQT-1213 7mg | Total |
|---|---|---|---|---|---|
| Mean | 27.35 ± 3.365 | 26.99 ± 2.942 | 30.82 ± 6.971 | 33.33 ± 7.560 | 28.57 ± 4.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in May 2024, 14 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thryv Therapeutics, Inc.